Table 4 Vedolizumab therapy outcomes and clinical characteristics (n = 28)
Characteristic | Clinical remission, No. (%) | Clinical failure, No. (%) |
|---|---|---|
Total no. of patients | 24 | 4 |
Checkpoint inhibitor type | ||
CTLA-4 | 6 (25) | 2 (50) |
PD-1/L1 | 11 (46) | 1 (25) |
Combination | 7 (29) | 1 (25) |
Mean duration of steroid therapy, days(SD) | 95 (79) | 99 (52) |
Median time from symptom onset to vedolizumab/infliximab therapy, days (IQR) | 19 (6–152) | 9 (4–67) |
Median no. of vedolizumab doses (IQR) | 3 (1–4) | 3 (1–4) |
Mean fecal calprotectin level at time of onset μg/g (SD) | 299 (236) | 586 (584) |
Peak grade of diarrhea | ||
2 | 12 (50) | 2 (50) |
3–4 | 12 (50) | 2 (50) |
Initial endoscopic findings | ||
Ulceration | 6 (25) | 3 (75) |
Nonulcerative inflammation | 12 (50) | 0 (0) |
Normal | 6 (25) | 1 (25) |
Initial histologic findings | ||
Active features | 24 (100) | 4 (100) |
Chronic features | 10 (42) | 4 (100) |
Microscopic | 9 (38) | 1 (25) |
Mean overall duration of disease months (SD) | 5 (3) | 8 (5) |
Mean fecal calprotectin level after vedolizumab therapy μg/g (SD) | 187 (108) | 270 (487) |
Last repeat endoscopic findingsa | ||
Ulceration | 1 (8) | 3 (75) |
Nonulcerative inflammation | 6 (46) | 0 (0) |
Normal | 6 (46) | 1 (25) |
Active features on last repeat histologic analysisa | 9 (69) | 4 (100) |